Muhammad Hassan

Muhammad Hassan

Auto-generated profile, based on publicly available information

Muhammad Hassan

Department of Internal Medicine Punjab Medical College Faisalabad Punjab Pakistan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2026 in Health Science Reports
Verified
Journal Article
Open access
MAMuhammad Husnain Ahmad
Muhammad Husnain Ahmad
MAMasab Ali
Masab Ali
MHMuhammad Hassan
Muhammad Hassan
RARehan Naseer Ahmad
Rehan Naseer Ahmad
MYMuhammad Usama Yasin
Muhammad Usama Yasin
MSMuhammad Sajjad
Muhammad Sajjad
Background and Aims: Families of children with special needs face sustained emotional, psychological, and social challenges that can profoundly influence both caregiver well‐being and child health outcomes. Primary care clinicians are uniquely positioned to address these needs longitudinally, yet the psychosocial dimensions remain under‐recognized in routine practice. This review aims to synthesize existing evidence on caregiver burden and identify opportunities for enhanced primary care engagement. Methods: A narrative review was conducted using PubMed, PsycINFO, and Google Scholar to identify articles on “caregiver burden,” “special needs children,” and “primary care support.” Eligible studies included peer‐reviewed research, reviews, and guidelines addressing psychosocial outcomes and primary care interventions. Literature was analyzed through a primary care perspective, emphasizing caregiver mental health, family functioning, and healthcare system navigation. Results: Evidence consistently demonstrates high rates of caregiver stress, anxiety, depression, and burnout, compounded by marital strain, role imbalance, and financial burden. Key risk factors include socioeconomic disadvantage, fragmented care coordination, and lack of culturally responsive support. Protective factors encompass strong social networks, access to multidisciplinary care, and proactive primary care engagement. Despite existing guidelines advocating family‐centered models, gaps persist in systematic screening, timely referral pathways, and integration of psychosocial interventions into primary care workflows. Conclusion: The emotional and psychological health of families raising children with special needs is integral to optimal child outcomes. Primary care must evolve toward comprehensive, family‐centered frameworks that embed mental health screening, caregiver support, and coordinated interprofessional care into routine practice. Addressing these gaps will require policy alignment, workforce training, and targeted research to operationalize psychosocial support as a core element of pediatric primary care.

17 September 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
SSSufyan Shahid
Sufyan Shahid
HSHumza Saeed
Humza Saeed
MAMasab Ali
Masab Ali
MHMuhammad Hassan
Muhammad Hassan
SHSara Hira
Sara Hira
MAMuhammad Husnain Ahmad
Muhammad Husnain Ahmad
Background: Despite traumatic brain injury (TBI) being a leading cause of disability worldwide, it often results in long-term neurocognitive deficits. While conventional treatment options remain limited, hyperbaric oxygen therapy (HBOT) has been proposed as a potential adjunctive intervention due to its ability to enhance oxygen delivery and reduce inflammation. We performed a systematic review and meta-analysis to evaluate the efficacy of HBOT in improving neurocognitive outcomes for TBI patients. Methods: PubMed, Embase, and Cochrane Central databases were searched for studies on HBOT efficacy in neurocognitive deficits in TBI. Statistical analysis was performed using RevMan v.5.4. A random-effects model was applied to pool mean differences (MDs) and 95% confidence intervals ( P < 0.05). Risk of Bias 2 (RoB-2) and Risk of Bias in Non-Randomized Studies of Interventions (ROBINS-I) tools were used to assess the risk of bias in included randomized controlled trials (RCTs) and non-randomized studies (NRSs), respectively. Results: Across four studies (250 patients; mean age 25 years, 43% female), HBOT significantly improved multiple neurocognitive domains in TBI patients. The most pronounced improvements were observed in memory (MD 10.13, P < 0.00001) and attention (MD 7.99, P < 0.00001), with additional benefits in general cognition scores (MD 7.47, P = 0.003), executive function (MD 7.16, P = 0.002), information processing speed (MD 7.48, P = 0.01), and motor skills (MD 5.19, P < 0.00001). RCTs had a low risk of bias, while NRSs had a moderate risk of bias due to confounding. Conclusion: HBOT demonstrates potential in mitigating neurocognitive impairments associated with TBI. Proposed mechanisms underlying its effects include enhanced oxygenation, reduced inflammation and expression of matrix metalloproteinase, decreased brain swelling, and improved outcomes. However, larger trials with standardized protocols are needed to establish the optimal therapeutic role of HBOT in TBI management.

16 April 2025 in Health Science Reports
Verified
Journal Article
Open access
HSHashim Mohamed Siraj
Hashim Mohamed Siraj
MAMasab Ali
Masab Ali
SSSampda Sanjaykumar Sharma
Sampda Sanjaykumar Sharma
ABAfreen Begum
Afreen Begum
MAMuhammad Husnain Ahmad
Muhammad Husnain Ahmad
MTMuhammad Hamza Tahir
Muhammad Hamza Tahir
Background and Aims: Drug‐induced renal vasculitis arises from various medications that cause immunological dysregulation or direct vascular damage, leading to inflammation and thrombosis. Clinical manifestations vary widely, from mild constitutional symptoms to severe organ dysfunction. This review aims to thoroughly explore drug‐induced renal vasculitis, focusing on its etiology, pathological mechanisms, clinical manifestations, diagnostic challenges, and therapeutic approaches. This review aims to summarize current knowledge and highlight areas requiring further research.Methods: A comprehensive literature search was conducted using PubMed, MEDLINE, Embase, and Cochrane Library databases. We included peer‐reviewed journal articles and excluded those with insufficient data, poor quality, or lack of relevance. The search terms included combinations of “renal vasculitis,” “drug‐induced vasculitis,” “drug‐related nephritis,” “medication‐induced renal vasculitis,” and specific drug names. An initial search yielded 13,192 articles, of which 13,103 were excluded due to irrelevance, duplication, or outdated information. After full‐text review, 99 peer‐reviewed articles were included.Results: Discontinuation of the offending drug is the primary and most crucial step in managing drug‐induced renal vasculitis. Prognosis is generally more favorable than primary vasculitis, with a high remission rate if the offending drug is stopped early. Due to its rarity, epidemiological data is limited. Diagnosis frequently relies on autoantibodies [antineutrophil cytoplasm antibodies (ANCA), myeloperoxidase (MPO), antinuclear antibody (ANA)] and clinical symptoms, with renal biopsy confirming it. Factors such as high‐dose and long‐term drug use, as well as genetic predispositions, increase the risk.Conclusion: This review provides a comprehensive overview of drug‐induced renal vasculitis, discussing what is known and identifying gaps in understanding. While discontinuing the causative drug remains the cornerstone of management, further research is needed, particularly in developing a formal tool to assess the quality of studies and minimize selection bias.

13 March 2026 in Medicine
Verified
Journal Article
Open access
MAMasab Ali
Masab Ali
RARehan Mbbs Naseer Ahmad
Rehan Mbbs Naseer Ahmad
MHMuhammad Mbbs Hassan
Muhammad Mbbs Hassan
MHMoiz Ul Haq Hashmi
Moiz Ul Haq Hashmi
MKMadiha Kiyani
Madiha Kiyani
MRMuhammad Mbbs Riyyan
Muhammad Mbbs Riyyan
Sepsis patients are highly susceptible to atrial fibrillation (AF) and atrial flutter due to the proinflammatory and adrenergic milieu, which precipitates arrhythmogenesis, especially in vulnerable individuals. Understanding mortality trends and disparities in this population is essential for targeted interventions. We analyzed US death certificates from the Center of Disease Control Wide-Ranging Online Data for Epidemiologic Research database for individuals aged ≥25 years who died between 1999 and 2023 with both sepsis and AF listed as causes. We calculated age-adjusted mortality rates (AAMRs), which measure changes in death rates over time while accounting for differences in age distribution, and annual percent change to evaluate yearly trends in these rates across demographic groups stratified by year, sex, age group, race/ethnicity, geographic region, and urbanization status. A total of 2,40,222 deaths involved both AF/atrial flutter and sepsis. The overall AAMR increased from 2.0 per 1,00,000 in 1999 to a peak of 7.9 in 2021 (annual percent change +5.6% through 2018, accelerating to +12.6% through 2021), with a slight decline to 7.1 by 2023. Mortality was consistently higher in men than women, older adults, residents of nonmetropolitan areas, and the US South. By race/ethnicity, non-Hispanic White and Black individuals had the highest AAMRs, followed by American Indian/Alaska Native, Hispanic, and Asian/Pacific Islander populations. Deaths involving AF and sepsis have risen substantially over the past 4 decades, with sharp increases in recent years and persistent disparities by age, sex, race/ethnicity, and geography. These findings underscore the need for integrated arrhythmia–sepsis management strategies, enhanced access to critical care in underserved regions, and equity-focused public health interventions to mitigate mortality.

27 March 2026 in Health Science Reports
Verified
Journal Article
Open access
ALAyesha Laraib
Ayesha Laraib
UAUswa Ahmad
Uswa Ahmad
SLSyeda Iman Laraib
Syeda Iman Laraib
SLSyeda Wardah Laraib
Syeda Wardah Laraib
MAMasab Ali
Masab Ali
MHMuhammad Hassan
Muhammad Hassan
Background and Aims: The rising global prevalence of obesity has catalyzed the development of potent glucagon‐like peptide‐1 (GLP‐1) receptor agonists. This narrative review evaluates the efficacy, safety, and practical considerations of injectable semaglutide for weight management, specifically in non‐diabetic adults, a population where weight loss outcomes often differ from those seen in diabetic cohorts. Methods: Using information from PubMed, Scopus, and Web of Science, a thematic synthesis was carried out under the guidance of the SANRA procedural framework (2019–2025). The search used tirzepatide as a comparative benchmark and a particular Boolean string to target semaglutide efficacy in non‐diabetic groups. To evaluate metabolic effects and practical obstacles, data from 27 studies including observational studies, randomized controlled trials (RCTs), and qualitative reports, were analytically combined. Results: In adults without diabetes, semaglutide (2.4 mg) shows better weight loss efficacy, with mean reductions of roughly 14.9% as opposed to 9.6% in diabetic groups. Significant improvements in cardiometabolic indicators and quality‐of‐life assessments were observed in addition to weight loss. Nevertheless, the main reason for stopping is still gastrointestinal side effects. Long‐term therapeutic utility is greatly impacted by practical obstacles, such as high out‐of‐pocket expenses, worldwide supply limitations, and the possibility of weight gain after cessation. Conclusion: Although semaglutide is a novel obesity disease‐modifying medication, its effectiveness depends on how well it is incorporated into multimodal treatment plans. Even though its effectiveness has been shown, equitable public health implementation requires addressing structural issues and safety concerns, such as drug pricing models and insurance coverage. Long‐term durability studies and head‐to‐head trials with next‐generation incretins should be the top priorities for future research.

27 July 2025 in Clinical Case Reports
Verified
Journal Article
Open access
SPSalman Pervaiz
Salman Pervaiz
AAAbeera Azam
Abeera Azam
MAMasab Ali
Masab Ali
MAMuhammad Husnain Ahmad
Muhammad Husnain Ahmad
PMPreetham Muskula
Preetham Muskula
MHMuhammad Hassan
Muhammad Hassan
Chest pain following left atrial appendage closure (LAAC) with the Watchman device is rare but can occur due to complications such as pericarditis or myocardial infarction. We present the case of a 59‐year‐old male with atrial fibrillation who developed sharp, left‐sided chest pain exacerbated by inspiration after undergoing Watchman device placement. Despite extensive diagnostic evaluations, including electrocardiograms (ECGs), echocardiograms, and cardiac catheterization, the exact cause of the pain remained unclear, with no signs of acute coronary syndrome or pericardial effusion. The patient's symptoms persisted despite treatment with colchicine and anti‐inflammatory agents including steroids. Due to the severe and persistent nature of the pain, the patient opted for surgical removal of the Watchman device. This procedure led to a significant resolution of his symptoms. This case underscores the need to consider device removal for persistent, idiopathic chest pain after LAA occlusion, especially when other causes are excluded and conservative management fails.